---
title: "CorMedix to join investor conferences in March. (Feb 12, 2026) - Nasdaq: CRMD. Expert management presenting."
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275769709.md"
description: "CorMedix Therapeutics (Nasdaq: CRMD) announced that its senior management will participate in investor conferences in March 2026. This engagement is part of the company's strategy to enhance investor relations and demonstrate commitment to transparency with stakeholders. CorMedix focuses on developing therapeutic products for critical diseases, making this involvement significant for those tracking its progress in the biopharmaceutical sector."
datetime: "2026-02-12T13:57:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275769709.md)
  - [en](https://longbridge.com/en/news/275769709.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275769709.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275769709.md) | [繁體中文](https://longbridge.com/zh-HK/news/275769709.md)


# CorMedix to join investor conferences in March. (Feb 12, 2026) - Nasdaq: CRMD. Expert management presenting.

CorMedix Therapeutics (Nasdaq: CRMD) from Berkeley Heights, N.J., shared today the news about their senior management's plans to present and engage in investor meetings at conferences scheduled for March 2026. The company is involved in developing and marketing therapeutic products for critical diseases and conditions. The involvement of senior management in these events signifies a significant step in the company's investor relations strategy and highlights their commitment to transparency and communication with stakeholders. Keep an eye out for these developments if you are closely following CorMedix Therapeutics' progress in the biopharmaceutical sector.

### 相关股票

- [Cormedix (CRMD.US)](https://longbridge.com/zh-CN/quote/CRMD.US.md)

## 相关资讯与研究

- [CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference](https://longbridge.com/zh-CN/news/279132884.md)
- [CorMedix stock drops after earnings: is this dip a buy before key catalyst?](https://longbridge.com/zh-CN/news/278056003.md)
- [Is CorMedix (CRMD) Pricing Reflect Recent Share Weakness Or Future Growth Potential](https://longbridge.com/zh-CN/news/277228722.md)
- [ADHD May Not Be A Disorder After All](https://longbridge.com/zh-CN/news/278647785.md)
- [ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B](https://longbridge.com/zh-CN/news/278816969.md)